Medical devices giant
St. Jude Medical, Inc.
) recently announced that it will be offering 3.25% senior notes
due 2023 for an aggregate purchase price of $900 million, and
also 4.75% senior notes due 2043 for an aggregate purchase price
of $700 million.
The net proceeds will be used primarily to redeem its earlier
debts via the 3.75% senior notes due 2014, of which $700 million
is outstanding, as well as the 4.875% senior notes due 2019, of
which $500 million is outstanding. The company may also use the
proceeds for general corporate purposes, including repayment of
St. Jude's debt-to-capital ratio at the end of the fourth
quarter of 2012 was 38.4%. Following the completion of the
offerings, the new ratio will be 50.3%. Moreover, net interest
expenses in 2012 were $73 million. The current favorable interest
rate environment should help the company lower interest expenses
Given St. Jude's strong cash balance, we believe that the
company will be able to meet its interest obligation. The company
exited the 2012-fourth quarter with cash and cash equivalents of
$1,194 million, up 21.1% from the previous-year quarter.
Long-term debt decreased 6% year over year to $2,550 million.
Additionally, STJ generated $1,335 million of operating cash flow
in 2012, up 3.7 year over year.
St. Jude has a Zacks Rank #3 (Hold). The company's
fourth-quarter adjusted earnings per share of 92 cents rose 7%
from the prior year and topped the Zacks Consensus Estimate by 2
The company's strong business fundamentals coupled with new
products are expected to drive long-term growth. However,
softness in the core Cardiac Rhythm Management ("CRM") market and
the noise surrounding its high-margin ICD leads are likely to
keep revenues under pressure.
While we remain on the sidelines regarding St. Jude, medical
products companies such as
) appear impressive. All these stocks carry a Zacks Rank #2
ABAXIS INC (ABAX): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis
ST JUDE MEDICAL (STJ): Free Stock Analysis
To read this article on Zacks.com click here.